Who inspects a compounding pharmacy's drug labels, the FDA or the state board of pharmacy?

Both can, depending on the pharmacy's registration and the matter. A 503A pharmacy's label content rules come from its state board of pharmacy, which is the inspector of record for them, while FDA inspects under its own authority when a compounded drug's 503A conditions are in question or when the pharmacy is a 503B outsourcing facility. A single labeling finding can draw review from either authority, and sometimes both, so the response should account for both standards.

Can a 503A pharmacy compound and label a drug that copies a commercially available product?

FDA's guidance on compounded drug products that are essentially a copy of a commercially available product, issued under section 503A, restricts a pharmacy from regularly or in inordinate amounts compounding a drug with the same active ingredient, the same, similar, or easily substitutable dosage strength, and the same route of administration as a commercially available product. A label that otherwise meets every content requirement does not cure a copy that falls outside this limit; the analysis looks at the formulation, not just the label.

Do compounded drugs need a package insert or FDA-style prescribing information?

Compounded drugs are not FDA-approved, so they do not carry the FDA-approved package insert or prescribing information of a commercial drug, and a pharmacy should not represent that they do. Any patient-facing information sheet or website claim describing a compounded product's use is a separate advertising question from the container-label content requirements covered here, and it carries its own state and federal scrutiny.

Labeling Compounded Drugs: What FDA and Board Inspectors Check

A compounded drug's label is the first thing an FDA investigator or a state board of pharmacy inspector checks, and a gap in it can escalate an otherwise routine visit. Pharmacies compounding under section 503A and outsourcing facilities registered under section 503B answer to different labeling standards: the required content, the statement that the drug is compounded, and the beyond-use date are not interchangeable between the two. A label missing a required element can turn a routine inspection into a misbranding finding, because the label is one of the facts FDA and state boards use to decide whether a compounder met the conditions that let it operate outside new-drug approval.

What a 503A Label Has to Show

Section 503A does not itself set a federal content checklist for a compounded drug's label. 21 U.S.C. § 353a(a) exempts a qualifying compounded drug from FDA new-drug approval, adequate-directions-for-use, and the current good manufacturing practice (CGMP) adulteration rule. The label content itself comes from the pharmacist's state board rules, which vary by state. Texas requires a compounded non-sterile label to carry each active ingredient's generic name, a statement that the preparation was compounded, and a beyond-use date, under 22 Tex. Admin. Code § 291.131(d)(5), so confirm the current state rule before a label ships.

The Compounded-Statement Requirement

No single federal statute requires every 503A label to carry the word compounded. That statement comes from the state board rule the pharmacy operates under, and its wording and placement vary by state. Section 503B carries a federal version of the same idea: the label of a drug compounded by an outsourcing facility must bear “the statement 'This is a compounded drug.' or a reasonable comparable alternative statement,” under 21 U.S.C. § 353b(a)(10)(A)(i). A 503A pharmacy and a 503B outsourcing facility can carry two differently worded compounded-statements on related products, and both can be correct for the entity that produced them.

Beyond-Use Date and Storage

The beyond-use date (BUD) is the date, or date and hour, after which a compounded preparation must not be used, and it runs from when the preparation was compounded, not from a manufacturer's expiration date. USP General Chapters <795> and <797> set default BUDs for nonsterile and sterile preparations absent a USP-NF monograph or stability data. The label itself must carry the assigned BUD and the storage condition it depends on, since a BUD assigned for refrigerated storage does not hold at room temperature. An inspector checks the BUD against the compounding record, not a figure carried over from a different preparation's extension analysis.

503B Outsourcing-Facility Labels Carry More

An outsourcing facility's label carries a longer federal list than a 503A pharmacy's. Under 21 U.S.C. § 353b(a)(10)(A), the label must show the facility's name, address and phone, the lot number, the drug's established name, dosage form and strength, quantity, date compounded, expiration date, storage instructions, the National Drug Code number if available, and active and inactive ingredients, the same detail a facility should track through its certificates of analysis. The label must also carry “Not for resale,” and, if the drug is not dispensed under an individual patient's prescription, “Office Use Only.”

When a Labeling Gap Becomes a Misbranding Charge

Section 503A's exemptions apply only while its conditions are met. A drug compounded outside the conditions in 21 U.S.C. § 353a loses the exemptions from new-drug approval, adequate-directions-for-use, and CGMP, and FDA has described drugs that fail those conditions as unapproved new drugs and misbranded drugs in its own warning letters. A missing compounded-statement or unsupported beyond-use date does not by itself prove a violation, but it is a finding an inspector records on the spot, and it can trigger a broader review of sourcing and other 503A conditions, including the limits on compounding before a prescription arrives. Package inserts and website claims about a compounded product raise a separate advertising question not addressed here.

The label is the first record an inspector checks to test whether a compounded drug actually met the conditions its exemption depends on.

Why Early Legal Counsel Is Critical

It is critical that compounding pharmacies and outsourcing facilities promptly retain experienced healthcare defense counsel upon receiving an FDA Form 483, warning letter, or state board inspection finding tied to labeling. Early legal intervention can shape the response before a single label finding becomes a broader 503A compliance review, help avoid inadvertent admissions during the inspection, and let counsel communicate with the inspector or board on the pharmacy's behalf. Delaying representation can narrow the pharmacy's options once conclusions are already drawn from the label reviewed.

How Health Law Alliance Can Help

Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.

If your compounding pharmacy or outsourcing facility has received an FDA inspection finding, a warning letter, or a state board citation involving label content, contact Health Law Alliance's compounding pharmacy attorneys for a free, confidential consultation before responding.

Labeling Compounded Drugs: What FDA and Board Inspectors Check

What a 503A Label Has to Show

The Compounded-Statement Requirement

Beyond-Use Date and Storage

503B Outsourcing-Facility Labels Carry More

When a Labeling Gap Becomes a Misbranding Charge

Why Early Legal Counsel Is Critical

How Health Law Alliance Can Help

Frequently asked

More from Compounding Pharmacy

Master Formulation Records and Compounding Records Under Inspection

Florida Permits for Compounding Pharmacies and Outsourcing Facilities

Common FDA Form 483 Observations at 503A Compounding Pharmacies